Kimberly Perez

机构：Harvard University, Dana-Farber Cancer Institute · ORCID：0000-0002-5745-2994

发表论文 448 篇 · 总被引 3644 次 · h-index 26

代表论文

Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer (2026 · medRxiv)
Supplementary Table S5 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors (2026)
Supplementary Figure S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2 (2026)
Supplementary Figure S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2 (2026)
Supplementary Figure S6 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2 (2026)
Supplementary Figure S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors (2026)